Stockscreener 앱 받기
19.07
0.00%
0.00
시간 외 거래:
19.05
-0.02
-0.10%
전일 마감가:
$19.07
열려 있는:
$19.07
하루 거래량:
1.55M
Relative Volume:
0.95
시가총액:
$1.93B
수익:
$54.55M
순이익/손실:
$-193.57M
주가수익비율:
-6.5986
EPS:
-2.89
순현금흐름:
$-181.86M
1주 성능:
+5.42%
1개월 성능:
+56.70%
6개월 성능:
+59.45%
1년 성능:
-7.25%
1일 변동 폭
$19.06
$19.68
1주일 범위
$19.02
$22.50
52주 변동 폭
$8.18
$22.50
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
19.07 | 1.93B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Redmile Group LLC Lowers Stake in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Optimistic Investors Push Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Up 48% But Growth Is Lacking - 富途牛牛
Nurix prices 24.5M shares at $10.21 in underwritten registered offering - MSN
Cathie Wood Reduces Iridium Holdings While Adding Biotech Stock Nurix Therapeutics - parameter.io
Why Cathie Wood Just Sold Millions in Iridium and Bought This Biotech Stock - CoinCentral
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday - Investing.com
What insider trading reveals about Nurix Therapeutics Inc stockMarket Activity Report & Risk Controlled Daily Plans - moha.gov.vn
Mizuho Maintains Nurix Therapeutics (NRIX) Outperform Recommendation - Nasdaq
NRIX: Mizuho Raises Price Target, Maintains Outperform Rating | - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 at Mizuho - MarketBeat
Nurix stock price target raised to $31 from $28 at H.C. Wainwright - Investing.com UK
NRIX: HC Wainwright & Co. Raises Price Target for Nurix Therapeu - GuruFocus
Mizuho Adjusts Price Target on Nurix Therapeutics to $30 From $24, Maintains Outperform Rating - marketscreener.com
BTIG Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 5.4%Here's Why - MarketBeat
NRIX Analyst Rating Update: BTIG Raises Price Target | NRIX Stoc - GuruFocus
Nurix (NRIX) soars 18.7% on encouraging blood cancer treatment trial - MSN
Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial - Insider Monkey
Nurix Therapeutics Reports Promising Data at Hematology Meeting - TipRanks
NRIX: Bexobrutideg achieved a 75% response rate with durable, well-tolerated outcomes in Waldenström macroglobulinemia - TradingView
Nurix Therapeutics Presents New Clinical Data at ASH Annual Meeting - TradingView
Nurix reports 75% response rate for bexobrutideg in WM patients By Investing.com - Investing.com Australia
10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs - Insider Monkey
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpTime to Buy? - MarketBeat
Needham Reiterates Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
Could This Biotech, Up 35%, Have The Next Dupixent? - Investor's Business Daily
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg in Waldenström Macroglobulinemia at the 67th American Society of Hematology Annual Meeting and Exposition - Investing News Network
Nurix reports 75% response rate for bexobrutideg in WM patients - Investing.com
NRIX Clinical Trial Data Highlights Promising Results for Bexobr - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Earns Buy Rating from Needham & Company LLC - MarketBeat
Nurix Therapeutics Reports 75% Objective Response Rate for Bexobrutideg in Heavily Pre-treated Waldenström Macroglobulinemia Patients at ASH Annual Meeting - Quiver Quantitative
Nurix Therapeutics presents new data from the phase 1 trial of bexobrutideg in Waldenström macroglobulinemia at the 67th American Society of Hematology annual meeting and exposition - marketscreener.com
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - Yahoo Finance
Nurix Therapeutics (NRIX): Analyst Reiterates Buy Rating, Mainta - GuruFocus
NRIX Shows Promising Results in Phase 1a/1b Clinical Trial for B - GuruFocus
Bollard Group LLC Makes New $1.40 Million Investment in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting & Ex - Investing News Network
Nurix reports 83% response rate for bexobrutideg in CLL patients - Investing.com
Nurix Therapeutics Reports Promising Phase 1a/1b Clinical Data for Bexobrutideg in Patients with Relapsed or Refractory CLL, Showcasing 83% Objective Response Rate and 22.1 Months Median Progression-Free Survival - Quiver Quantitative
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (AS - The Manila Times
Affinity Asset Advisors LLC Increases Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Is Nurix Therapeutics Inc. stock positioned for long term growthPortfolio Risk Summary & Low Drawdown Trading Techniques - Newser
In the Wake of Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Latest US$86m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
Nurix Therapeutics (NRIX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast - Yahoo Finance
What is the fair value of Nurix Therapeutics Inc. stock now - Newser
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Is the Upcoming NX-5948 Clinical Data Update Shaping the Investment Case for Nurix Therapeutics (NRIX)? - simplywall.st
Nurix to host webcast on bexobrutideg clinical data next week By Investing.com - Investing.com Canada
Nurix to host webcast on bexobrutideg clinical data next week - Investing.com
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):